| Previous close | 4,768.50 |
| Open | 4,813.50 |
| Bid | 4,790.00 x 6100 |
| Ask | 4,975.00 x 13000 |
| Day's range | 4,772.50 - 4,954.50 |
| 52-week range | 3,996.00 - 5,520.00 |
| Volume | 3,343,608 |
| Avg. volume | 2,419,468 |
| Market cap | 62.18B |
| Beta | 0.63 |
| PE ratio (TTM) | 16.11 |
| EPS (TTM) | 304.9 |
| Earnings date | 9 Nov 2017 |
| Dividend & yield | 2.79 (4.51%) |
| Ex-dividend date | 2017-08-10 |
| 1y target est | 67.31 |
- Motley Fool•9 hours ago
AstraZeneca Stock Upgraded: What You Need to Know
Bernstein sees opportunity in a buyout target.
- Financial Times•9 hours ago
[$$] AstraZeneca climbs as Bernstein backs takeover talk
AstraZeneca led the FTSE 100 higher on Friday after Bernstein Research said investors were wrong to write off the chances of another takeover approach. Bristol-Myers Squibb is seen as the most likely target ...
- Reuters - UK Focus•19 hours ago
BUZZ-AstraZeneca: return-to-growth story - Bernstein
** Bernstein ups AstraZeneca to "outperform", citing big pipeline and potential take-out ** Broker sees co's LT EPS growth among the very best of the 9 major EI/US pharma cos it covers ** Bernstein ...
